Clinical trials: Prostatic Adenocarcinoma
Prostate Cancer (Adenocarcinoma)
The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer
The gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate cancer (77%-100%). Numerous studies have confirmed that GRPR PET imaging has emerged as a significant molecular imaging modality in prostate cancer…
- Trial name
- NCT07363382
- Testing
- 68Ga-G21, 68Ga-G23
- Where
- China
- Volunteers
- 6 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
This phase I trial is studying the side effects and best dose of temsirolimus when given together with hormone therapy in treating patients with relapsed prostate cancer. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00512668
- Testing
- leuprolide acetate, goserelin acetate, bicalutamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
This randomized phase III trial studies how well hypofractionated radiation therapy works compared to conventional radiation therapy after surgery in treating patients with prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT03274687
- Testing
- Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 241 sites in United States, Canada and 1 more
- Volunteers
- 296 people
- Sponsor
- NRG Oncology
Prostate Cancer
Guided Biopsy for Mapping Prostate Cancer
Evaluate the accuracy of HIT guided biopsies for mapping tumor foci with men undergoing prostatectomy.
- Trial name
- HIT (NCT01007214)
- Testing
- Prostatectomy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Roswell Park Cancer Institute
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
This phase II trial studies the effect of erdafitinib in treating patients with prostate cancer that grows and continues to spread despite the surgical removal of the testes or drugs to block androgen production…
- Conditions
- Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma
- Trial name
- NCT04754425
- Testing
- Biopsy, Biospecimen Collection, Erdafitinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Cancer
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
- Trial name
- NCT04148937
- Testing
- LY3475070, Pembrolizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Internal Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. PURPOSE: This clinical trial is studying the side effects and how well internal radiation therapy works in…
- Trial name
- NCT00573833
- Testing
- questionnaire administration, quality-of-life assessment, brachytherapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer
Purpose: This clinical trail will combine the chemotherapy drugs, Estramustine and Vinorelbine (Navelbine), on an intermittent therapy strategy based on PSA response in the treatment of hormone refractory prostate cancer.
- Trial name
- NCT00151086
- Testing
- Estramustine, Vinorelbine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00028769
- Testing
- bicalutamide, estramustine, etoposide
- Where
- 91 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Cancer, Prostate Cancer
Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01160705
- Testing
- docetaxel, RNA analysis, reverse transcriptase-polymerase chain reaction
- Where
- 5 sites in Ireland
- Volunteers
- 73 people
- Sponsor
- Cancer Trials Ireland
Prostate Cancer
Focal Prostate Radio-Frequency Ablation
The main purpose of this study is to evaluate the safety and efficacy of focal (targeted) Radio-Frequency Ablation (RFA) in men with low or intermediate-risk, clinically localized prostate cancer.
- Trial name
- NCT02328807
- Testing
- Radio-Frequency Ablation (RFA)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT03419234
- Testing
- Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel
- Where
- 672 sites in United States, Puerto Rico
- Volunteers
- 223 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Metastatic Prostate Cancer
Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer
Current therapies for Metastatic Pancreatic Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Metastatic Pancreatic…
- Trial name
- NCT00003533
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Burzynski Research Institute
Adenocarcinoma of Prostate
Carbon Ions Boost Followed by Pelvic Photon Radiotherapy for High Risk Prostate Cancer
The aim of this research project is to test the feasibility and safety of a new treatment schedule for high risk prostate cancer that allows the administration of high doses to the prostate tumor with a mixed beam approach of…
- Trial name
- NCT02672449
- Testing
- Carbon Ions Boost Followed by Pelvic Photon Radiotherapy
- Where
- Italy
- Volunteers
- 65 people
- Sponsor
- European Institute of Oncology
Prostate Adenocarcinoma
Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate Adenocarcinoma
Patients with locally confined prostate adenocarcinoma (clinical stage T1c - T2bN0M0, Gleason score 7, PSA 20 ng/ml) are assigned to one of two treatment arms.
- Trial name
- NCT02339948
- Testing
- SBRT
- Where
- 4 sites in United States
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- GenesisCare USA
Prostate Cancer Adenocarcinoma
Multi-omics Analysis of Prostate Derived Extracellular Vesicles: an Observational Retrospective Study for Prostate Cancer Diagnosis and Monitoring
Prostate cancer (PCa) is the most commonly diagnosed malignancy in men and a leading cause of cancer-related mortality worldwide.
- Trial name
- EXOMAP (NCT07355985)
- Volunteers
- 100 people
- Sponsor
- IRCCS San Raffaele
Prostate Adenocarcinoma
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.
- Trial name
- NCT06257693
- Testing
- enzalutamide
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Alessa Therapeutics Inc.
Prostate Cancer
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using triptorelin may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003026
- Testing
- bicalutamide, flutamide, triptorelin
- Where
- 17 sites in Belgium, Israel and 5 more
- Volunteers
- 966 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Radiotherapy - Adjuvant Versus Early Salvage
Radical prostatectomy (RP) is the most common curative approach offered to men with newly diagnosed prostate cancer. Unfortunately, up to half of these patients will have factors placing them at high risk of their cancer…
- Trial name
- RAVES (NCT00860652)
- Testing
- Adjuvant Radiotherapy, Early Salvage Radiotherapy
- Where
- 36 sites in Australia, New Zealand
- Volunteers
- 333 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Melanoma, Prostate Cancer
An Expanded Access Program for AM0010 (Pegilodecakin)
This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- NCT03554434
- Testing
- AM0010
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.